Android app on Google Play

Needham & Company Starts ResMed (RMD) at Hold

July 16, 2013 7:43 AM EDT Send to a Friend
Get Alerts RMD Hot Sheet
Price: $53.05 +0.23%

Rating Summary:
    5 Buy, 8 Hold, 1 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 0 | Down: 0 | New: 0
Trade RMD Now!
Join SI Premium – FREE
Needham & Company initiates coverage on ResMed (NYSE: RMD) with a Hold.

Analyst Mike Matson comments, "RMD is the leader in the maturing continuous positive airway pressure (CPAP) device market. We expect RMD's prices and market share to be pressured given declining Medicare reimbursement. Additionally, we believe that competition in the CPAP market is increasing. We believe that consensus estimates are too high and have positioned our estimates below consensus. Given this we are initiating coverage with a Hold rating."

For an analyst ratings summary and ratings history on ResMed click here. For more ratings news on ResMed click here.

Shares of ResMed closed at $45.04 yesterday.




You May Also Be Interested In


Related Categories

New Coverage

Related Entities

Needham & Company

Add Your Comment